Tonix Pharmaceuticals Holding Corp. — 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. Filed March 30, 2012. Tonix was a development-stage pharmaceutical company with no marketed products or product revenue. In October 2011, it completed a reverse merger/share exchange with Tonix Pharmaceuticals, Inc.; the financial statements reflect Tonix Pharmaceuticals, Inc. as the accounting predecessor.
Financial performance and position
- Revenue and margins: No revenue or cost of goods sold in 2011 or 2010; gross margin is therefore not meaningful.
- Expenses and loss: R&D expense was $1.16 million, up 98.2% from $584,298. General and administrative expense was $2.22 million, up 65% from $1.34 million. Operating loss was $3.38 million versus $1.93 million; net loss was $3.47 million versus $1.96 million. Basic and diluted loss per share was $0.16 versus $0.18.
- Cash flow: Cash used in operating activities was $2.64 million, compared with $1.23 million in 2010. Investing activities provided $302. Financing activities provided $2.61 million.
- Liquidity: At year-end, cash was $41,123, current assets were $143,553 and current liabilities were $925,276, resulting in a $781,723 working-capital deficit. Restricted cash of $60,177 collateralized a lease letter of credit.
- Debt and equity: Year-end secured convertible debentures totaled $2.075 million, bearing 8% interest and secured by a first-priority lien on company assets. Total liabilities were $2.88 million and stockholders’ deficiency was $2.45 million. The company raised $612,000 from stock sales and received $1.501 million net proceeds from debentures during 2011.
- Financing after year-end: From January through March 2012, the company reported $4.69 million in cash proceeds and exchanged $1.925 million of debentures for units. It stated that existing cash and the net proceeds of the 2012 financing were expected to fund operating expenses and capital equipment for approximately six months.
Material changes and business developments
- Tonix changed from a natural-resources business to a CNS-focused pharmaceutical developer through the October 2011 share exchange. Former Tonix Pharmaceuticals shareholders received approximately 85% of the post-transaction common shares.
- R&D spending rose with clinical, formulation and regulatory activity. G&A increased mainly due to payroll, professional services and office costs. The company recognized $435,651 of stock-based compensation in 2011, including accelerated vesting connected with the share exchange.
- At year-end, the company had $2.075 million of debentures outstanding. The 2012 financing subsequently triggered exchange provisions; the filing describes warrant and incentive-share issuances to debenture holders and placement agents.
Pipeline, outlook and principal risks
- TNX-102: A low-dose cyclobenzaprine formulation under development for fibromyalgia. The clinical portion of a comparative pharmacokinetic study was completed by year-end; analysis was expected in the first half of 2012. Subject to results and funding, Tonix planned a roughly 300-patient Phase 2b study, targeted to start in the third quarter of 2012 and estimated to cost approximately $15 million.
- TNX-105: A cyclobenzaprine formulation for PTSD. No clinical trials in PTSD patients had been conducted; future studies were contingent on development progress and resources. TNX-201 and TNX-301 were earlier-stage pipeline candidates.
- Management expected R&D and public-company costs to rise and losses to continue. The company had no commercial products, no product revenue and required additional financing; it warned that failure to obtain funds could force program reductions or cessation of operations.
- The independent auditor’s report included a going-concern explanatory paragraph, citing recurring losses, negative operating cash flow, working-capital and stockholders’ deficiencies, and the need for additional financing. The audit opinion otherwise stated that the financial statements were fairly presented under U.S. GAAP.
- Approval under the Section 505(b)(2) pathway was an intended strategy, not an assurance. FDA requirements, clinical outcomes, safety, manufacturing, patent challenges, competition, reimbursement and market acceptance could delay or prevent commercialization.
- Management reported ineffective disclosure controls and internal control over financial reporting due to material weaknesses in staffing, segregation of duties and technical accounting expertise; planned remediation included hiring and outside accounting support.
- The business relied heavily on contractors and related-party consultants, including entities controlled by CEO Seth Lederman. The filing disclosed consulting payments and other related-party arrangements.
Important facts for investors to verify
- Whether the TNX-102 pharmacokinetic results supported further development and whether planned clinical studies were initiated, funded and completed on schedule.
- Actual cash, burn rate, financing availability and runway after the 2012 financing, including its costs, dilution and warrant-related terms.
- Current debt and any remaining obligations arising from the secured debentures, conversion terms and subsequent financing.
- Progress in correcting the disclosed material weaknesses and whether controls improved in subsequent filings.
- Status and scope of FDA feedback, patent protection, related-party agreements and any changes to the company’s development plans.